https://www.selleckchem.com/pr....oducts/bupivacaine.h
SLPI induced osteoclastogenic genes including receptor activator of nuclear factor kappa-Β ligand (RANKL) and synergistically augmented the compression-induced RANKL and macrophage colony-stimulating factor (MCSF) expression. Finally, the in vivo SLPI application into the AB significantly augmented BTM. SLPI or its inhibitors might serve as a biological target molecule for therapeutic interventions to modulate BTM. SLPI or its inhibitors might serve as a biological target molecule for therapeutic interventions to modulate BTM.Tape s
Like
Comment
Share
